1 citations
,
October 2010 in “Cambridge University Press eBooks” This review discusses strategies for managing dermatological symptoms of hyperandrogenism in PCOS by reducing androgen levels and actions, and reports no new clinical results.
1 citations
,
September 2010 in “UEF eRepo (University of Eastern Finland)” This study provides insight into AR-mediated gene activation and the molecular mechanisms of prostate cancer progression and drug resistance, identifying potential avenues for developing new therapies.
1 citations
,
January 2010 This study in humans and pigs found that finasteride metabolism is significantly influenced by CYP3A4, with induced metabolism decreasing and inhibited metabolism increasing plasma exposure of the drug.
1 citations
,
December 2005 in “Al-Mağallaẗ al-ʻirāqiyyaẗ li-l-ṣaydalaẗ” In this clinical study, melatonin treatment reduced oxidative stress markers and enhanced hair growth in patients with alopecia areata, potentially through its effects on the immune system and antioxidant activity.
1 citations
,
January 2005 in “PubMed” This review explores current concepts of steroid action in skin health and healing but provides no new clinical findings.
1 citations
,
January 1996 This study found that cysteine and arginine are crucial for hair growth in hair follicles, with cysteine affecting hair fibre diameter and arginine involved in protein incorporation and energy metabolism.
1 citations
,
January 1978 in “PubMed” This study found that certain synthetic corticosteroid and progesterone analogues inhibited hair growth in castrated male mice, with varying effects based on specific chemical modifications.
January 2026 in “Dermatology Review” In this study, the authors highlighted that celiac disease can have various skin manifestations such as dermatitis herpetiformis and psoriasis, which may precede or occur without digestive symptoms, stressing the importance of screening in patients with unexplained dermatoses.
December 2025 in “Naunyn-Schmiedeberg s Archives of Pharmacology” In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.
June 2025 in “Journal of Endocrinological Investigation” This review identifies and discusses various endocrine-related causes of hypertension in children and adolescents, emphasizing the role of genetic predispositions and highlighting the need for systematic diagnostic guidelines and genetic sequencing referrals to improve diagnosis and treatment strategies.
January 2025 in “International Journal for Research Trends and Innovation” This review examines the factors contributing to Polycystic Ovary Syndrome in India, discussing genetic, lifestyle, and environmental influences, but provides no new clinical results.
March 2024 in “Cytologia” In this study, researchers observed that melatonin-mediated LncRNA MTC in Liaoning cashmere goat skin fibroblasts enhances cell proliferation by interacting with the GSTM1 protein, affecting its complex formation with ASK1 and thereby inhibiting apoptosis, which may be relevant for improving cashmere growth.
October 2020 in “Veterinary Dermatology” This review discusses autoimmune blistering diseases across species and highlights new treatment efficacy findings and ongoing trials, but it reports no new clinical results.
November 2013 in “John Wiley & Sons, Ltd eBooks” This chapter reviews various mucocutaneous manifestations of endocrine disorders and provides illustrative images of these clinical features, but reports no new research findings.
June 2011 in “Expert Review of Dermatology” Researchers discovered potential origins and new treatments for skin cancer, including biomarkers for melanoma and therapies that reduce tumor growth.
September 2002 in “Comprehensive Therapy” Primary care is key in managing PCOS, focusing on lifestyle changes and medications like birth control and metformin.
August 2026 in “Dermatology and Therapy” In this study, patient-reported outcomes indicated that greater weight loss with GLP-1RA treatments was associated with increased reports of adverse cosmetic effects such as skin laxity, facial volume loss, and hair shedding, despite improvements in some preexisting inflammatory skin conditions.
August 2026 in “Journal of Clinical Medicine” In this study, researchers found that the management of alopecia areata in Poland is inadequate, despite following international guidelines, due to limited access to advanced treatments and insufficient use of severity assessments and psychosocial support.
July 2026 in “Journal of Ovarian Research” In this review, researchers provided a comprehensive analysis of anti-androgen therapies for polyendocrine metabolic ovarian syndrome (PMOS/PCOS), examining their efficacy and safety while proposing a phenotype-guided management framework and highlighting research gaps, such as long-term cardiovascular safety and predictive biomarkers.
July 2026 in “Psychoneuroendocrinology” In this study, hair glucocorticoid levels, including cortisol and cortisone, showed varied associations with psychosocial stress factors, influenced by covariates like sex, age, and individual behaviors.
July 2026 in “Materials Today Bio” This study developed a novel hydrogel that improved healing in diabetic infected wounds on mobile sites by controlling infection, inflammation, and mechanical stress, promoting skin regeneration without excess scarring.
July 2026 in “Journal of the American Academy of Dermatology” GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.
June 2026 in “Quality in Sport” This narrative review found that combined oral contraceptives remain the primary treatment for hirsutism and acne in women with PCOS, but highlighted the need for further research to refine therapeutic options given the variable efficacy and emerging treatments like GLP-1 receptor agonists.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This case presentation highlights a 26-year-old woman with PCOS, metabolic syndrome, and prediabetes, emphasizing the importance of early recognition and multidisciplinary management to prevent long-term metabolic complications.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This case study details a 26-year-old woman diagnosed with PCOS and metabolic syndrome, highlighting the importance of early recognition and multidisciplinary management to improve reproductive and metabolic health outcomes.
June 2026 in “The Russian Archives of Internal Medicine” This case report detailed a 38-year-old woman with thallium intoxication, who initially presented with polyneuropathy and alopecia. The diagnosis was confirmed by toxicology, and treatment with potassium hexacyanoferrate led to full recovery, underscoring the importance of early diagnosis and treatment in toxic polyneuropathies.
May 2026 in “Reviews in Endocrine and Metabolic Disorders” This review explores weight loss interventions during gestation, emphasizing incretin-based therapies' potential to enhance reproductive health and address metabolic changes for better maternal and fetal outcomes.
May 2026 in “SKIN The Journal of Cutaneous Medicine” In this case report, a 60-year-old woman with alopecia areata and type 1 diabetes experienced hypoglycemic seizures after starting baricitinib, though reducing the dose alleviated these episodes; the study highlights the need for caution and glucose monitoring when using JAK inhibitors in at-risk patients.
May 2026 in “International Journal of Innovative Technologies in Social Science” This review reports that lifestyle modification, including diet and exercise, is essential for managing PCOS, while pharmacological and complementary treatments address specific symptoms like menstrual irregularities and insulin resistance.
May 2026 in “SHILAP Revista de lepidopterología” In this case report, a 7-year-old girl with severe alopecia areata and high baseline IgE levels achieved complete hair regrowth after 48 weeks of dupilumab therapy, with observed decreases in IgE levels and no significant adverse effects beyond a mild initial allergic reaction.